Due to their lack of receptors/molecular targets, triple negative breast cancers (TNBCs) have more limited treatment options than those that express ER and PR or overexpress HER2 and EGFR, which can be used as targets for therapy. This evidence concerns the gene EGFR and triple-negative breast carcinoma.